European Anticoagulants Market Share 2021: Trends, Key Players, Industry Analysis and Report 2021-2027

European anticoagulants market is estimated to grow at a CAGR of 6.6% during the forecast period. A significant rise in the demand for NOACs has been reported in the region, which in turn, is accelerating the market growth. The use of novel oral anticoagulants (NOACs) is growing significantly in Europe as their advantages over older drugs including warfarin. NOACs have demonstrated tremendous safety and efficacy without the requirement of subsequent dose adjustment and frequent monitoring. The three NOACs that are available in the EU market include Factor Xa inhibitors Xarelto (rivaroxaban) from Bayer, Boehringer Ingelheim’s thrombin inhibitor Pradaxa (dabigatran), and Pfizer/Bristol-Myers Squibb’s Eliquis (apixaban).

A full report of European Anticoagulants Market is available at: https://www.omrglobal.com/industry-reports/european-anticoagulants-market

These NOACs have practical benefits over vitamin k antagonists as they do not need monitoring and complex dose titration and have fewer interactions with food and other drugs. Some common factors that encourage patients to move from vitamin K antagonists to NOACs comprise mobility problems. Vitamin K antagonists require increased visits required as well as complaints regarding dose adjustments and discomfort including pain or bruising. The interest of Daiichi Sankyo interest in the field is focused on a Factor Xa antagonist referred to as Lixiana (edoxaban). It is available on the market in Japan, Europe, and the US.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/european-anticoagulants-market

Scope of the European Anticoagulants Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type and Application
• Regions Covered- UK, Germany, France, Spain, Italy, and Rest of Europe
• Competitive Landscape- Johnson & Johnson Services, Inc., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the European Anticoagulants Market

• In July 2020, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a generic version of apixaban, an anticoagulant medicine. In the meantime, the US FDA approved a generic version of chlorzoxazone, a muscle relaxant. Apixaban is an anticoagulant that is used for the treatment and prevention of blood clots and prevention of stroke. In 2011, it was first approved for use in the EU and is sold with the brand name Eliquis by Pfizer/Bristol-Myers Squibb.
• In November 2020, Boehringer Ingelheim declared the European Medicines Agency’s (EMA) Committee has adopted a positive opinion for Pradaxa (dabigatran etexilate) to treat venous thromboembolic events (VTE) and prevention of recurrent VTE in pediatric patients from birth to less than 18 years of age.

Key questions addressed by the report

• What is the market growth rate?
• Which segment/country dominates the market in the base year?
• Which segment/country will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19forecast
o Most affected segment/country
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

European Anticoagulants Market-Segmentation

By Type

• Novel Oral Anticoagulants (NOACs)
• Vitamin K Antagonist
• Heparin and Low Molecular Weight Heparin (LMWH)
By Application
• Pulmonary Embolism
• Atrial Fibrillation/Myocardial Infarction (Heart Attack)
• Deep Vein Thrombosis (DVT)
• Others

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/european-anticoagulants-market

European Anticoagulants Market– Segment by Country

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Company Profiles

• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb Co.
• Daiichi Sankyo Company, Ltd.
• GlaxoSmithKline plc
• Mylan N.V.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.